Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPACe 2 STAR: Therapeutic drug monitoring of risperidone in children with autism spectrum disorder
2020-005450-18Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of risperidone in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Metabolic abnormalities. Started Jun 2021; status: active.
02
Drugs
risperidone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2020-005450-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005450-18.